Tosan Tablet 50mg

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

LOSARTAN POTASSIUM

Boleh didapati daripada:

IMEKS PHARMA SDN. BHD.

INN (Nama Antarabangsa):

LOSARTAN POTASSIUM

Unit dalam pakej:

30Tablet Tablets; 100Tablet Tablets; 500Tablet Tablets; 50Tablet Tablets

Dikeluarkan oleh:

T.O. CHEMICALS (1979) LTD.

Ciri produk

CONTENTS
Each tablet contains Losartan Potassium 50.0mg
DESCRIPTION
White oval biconvex film coated tablet with half score and letter
C, L on one side and figure 50 on the other side.
PHARMACODYNAMICS
Angiotensin II is a potent vasoconstrictor, the primary vasoactive
hormone
of
the
renin-angiotensin
system
and
an
important
component in the pathophysiology of hypertension. Angiotensin
II also stimulates aldosterone secretion by the adrenal cortex
and smooth muscle cell proliferation. Losartan and its active
carboxylic acid metabolite are specific angiotensin II receptor
(type AT
1
) antagonist. AT
1
receptor can be found in many tissues
in the body (e.g. vascular smooth muscle, adrenal gland, kidneys
and
heart).
Losartan
inhibits
systolic
and
diastolic
pressor
responses to angiotensin II infusions by binding selectively to
the AT
1
receptor, resulting in blockage of vasoconstriction and
the release of aldosterone.
The
removal
of
angiotensin
II
negative
feedback
on
renin
secretion during treatment with losartan gave rise to plasma
renin activity and this leads to increase angiotensin II in plasma.
Even with these increases,
the antihypertensive activity and
suppression
of
plasma
aldosterone
concentration
are
maintained,
indicating
an
effective
angiotensin-II
receptor
blockade.
Losartan does not block or bind to other hormone receptors or
ion channels which are important in cardiovascular regulation.
Generally,
losartan
has
been
shown
to
block
responses
to
angiotensin I and angiotensin II without affecting responses to
bradykinin.
It
also
does
not
inhibit
Angiotensin-converting
enzyme
(ACE
or
kininase
II),
the
enzyme
that
degrades
bradykinin.
In
non-diabetic
hypertensive
patients
with
proteinuria,
the
administration
of
losartan
significantly
reduces
proteinuria,
fractional
excretion
of
albumin
and
IgG,
besides
maintains
glomerular filtration rate and reduces filtration fraction in these
patients. Losartan also caused a transient increase in urinary uric
acid excretion (usually < 24 micromol) which was persistent in